Hepatitis and cancer transformation
Conditions
Interventions
Liver Disease:None
Control:None
Hepatic fibrosis:None
compensatory Liver cirrhosis:None
Liver Cancer:None
Sponsors
The Second Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.(1) patients with hepatitis B and patients with non-alcoholic fatty liver disease in the liver disease group met the diagnostic criteria of the guidelines for Prevention and treatment of chronic Hepatitis B (2022 Edition). Inclusion criteria for patients with non-alcoholic fatty liver disease: in accordance with the diagnostic criteria of the guidelines for the Prevention and treatment of non-alcoholic Fatty liver Disease (updated 2018); According to Metavir staging and liver transient elastic ultrasound, the patients were divided into two groups: non-fibrosis group and fibrosis group (including significant fibrosis and progressive fibrosis): 1). normal ALT with LSM 2; PLT 1.3 Albumin 2cm;3) at the same time, the tumor marker alpha-fetoprotein (AFP) >= 400ug / kg, excluding pregnancy, hepatitis or metastatic liver cancer; 4) liver histopathological examination conformed to the diagnostic criteria of primary hepatocellular carcinoma (HCC); 5) according to the CSCO2023 guidelines for primary liver cancer, TNM stage belonged to early and middle stage (I, II, III); 6) there were complete data of anti-tumor treatment. 2.Control group: select healthy individuals who underwent physical examinations at the hospital during the same period, with normal liver function indicators.
Exclusion criteria
Exclusion criteria: 1.(1) patients who do not meet the above inclusion criteria; (2) hepatitis, cirrhosis and liver cancer caused by other liver diseases, such as autoimmune liver disease, drug-induced liver damage, alcoholic liver disease, etc.; (3) complicated with severe heart, kidney and hematopoietic system diseases, patients with other tumor diseases, mental illness; (4) pregnant or lactating women. 2.Control group: history of hepatitis, liver function damage, major surgeries, and diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabonomics;Proteomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholesterol;Triglycerides;Low-density lipoprotein cholesterol;High-density lipoprotein cholesterol;TCM syndrome scale; | — |
Countries
China
Contacts
Public ContactSun Tao
The Second Affiliated Hospital of Zhejiang Chinese Medical University (Xinhua Hospital of Zhejiang Province)
Outcome results
None listed